NCT06892288: An ongoing trial by Glycomine, Inc.
This trial is ongoing. It must report results 1 year, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06892288 |
|---|---|
| Title | A Phase 2b, Multicenter, Double-blind, Randomized, Placebo Controlled Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 Administered Intravenously to Participants With PMM2-CDG (POLAR Trial) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 9, 2025 |
| Completion date | Jan. 31, 2026 |
| Required reporting date | Jan. 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |